RxDoctor Payments Data

Charles Fuenzalida, MD

Cardiovascular Disease · Aurora, CONPI 1730175688

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $21,075 of the $29,943 with a category attached, or 70.4%. Medical Device Business Services, Inc. accounts for 68.5% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2024 at $9,538 and has fallen 57.0% since, to $4,097 in 2025. Among cardiovascular disease clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$29,943in general payments, 2019–2025

Across 278 payments — averaging $107.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$20K
  • Boston Scientific$2K
  • Biosense Webster, Inc.$2K
  • Medtronic$601
  • Impulse Dynamics (USA) Inc.$379
  • Sanofi-aventis U.S. LLC$378
  • plus $4K from 34 others
$3,996in research payments, 2019–2025

Across 23 payments — averaging $173.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biotronik Inc.$4K

What the payments were for

  • Consulting fees$21,07570%
  • Travel & lodging$2,1607%
  • Food & beverage$6,70822%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,943 in reported general payments places this provider in the 90th percentile of 276 cardiovascular disease providers in Colorado.

See all cardiovascular disease providers in Colorado

Medicare billing

Part B allowed, 2024
$260,808
Medicare patients
1,814
Services billed
6,068

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban668$801,476
XareltoRivaroxaban139$197,820
MultaqDronedarone Hcl95$113,205
JardianceEmpagliflozin81$88,403
Repatha SureclickEvolocumab39$39,905
FarxigaDapagliflozin Propanediol38$32,437
EntrestoSacubitril/Valsartan17$24,951
Dabigatran EtexilateDabigatran Etexilate Mesylate37$11,361
Dofetilide53$8,486
SotalolSotalol Hcl186$6,411
Verapamil Er PmVerapamil Hcl19$5,366
Flecainide Acetate97$4,642
Digoxin51$3,576
Propafenone Hcl ErPropafenone Hcl21$3,516
Eplerenone35$2,802

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$366$801,476668 claims
Johnson & JohnsonXarelto$331$197,820139 claims
Sanofi-aventis U.S. LLCMultaq$378$113,20595 claims
Boehringer IngelheimJardiance$168$88,40381 claims
NovartisEntresto$324$24,95117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 276 cardiovascular disease providers in Colorado.

Other cardiovascular disease in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →